Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer
Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial [...]
ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Top stories from 2020 for kidney cancer
Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the [...]
2020 top stories in kidney cancer
This article summarises the key breakthroughs in the treatment of [...]
Approach to selection of first-line treatment for advanced kidney cancer
During this online interview, the approach to selection of first-line [...]
Probiotic supplements and improves clinical benefit in kidney cancer
This prospective, randomised study in 20 people looked at the [...]
PDIGREE trial: Ipilimumab plus nivolumab with cabozantinib for untreated advanced kidney cancer
During this video interview from UroToday, Dr Tian Zhang from [...]
New survival data for pembrolizumab plus axitinib in advanced kidney cancer
A paper published in The Lancet Oncology this month provides [...]
